Background {#Sec1}
==========

The adaptive human immune system is able to recognize nearly any possible antigen even if it was never encountered before \[[@CR1], [@CR2]\]. This high variability is mediated by cell clone-specific, adaptive receptors on B and T cells, called B cell receptors (BCRs) and T cell receptors (TCRs). The development of B and T cells includes the introduction and repair of deoxyribonucleic acid (DNA) double strand breaks to form functional receptors \[[@CR3]\]. During this process, erroneous DNA recombination might lead to overexpression of proto-oncogenes, resulting in uncontrolled proliferation of single lymphocytes, eventually transforming into lymphoma \[[@CR4]\]. Almost 90% of these neoplasms derive from B cells \[[@CR5], [@CR6]\]. Despite the fact that the term Non-Hodgkin lymphoma is still widely used, it has been abandoned in the 2016 revision of the World Health Organization classification of lymphomas. Therefore, we use the currently accepted term of mature B cell neoplasm throughout this review \[[@CR7]\].

Mantle cell lymphoma (MCL), accounts for 3--10% of all lymphomas in Europe and the United States \[[@CR8]--[@CR10]\]. The median survival in the overall population of MCL patients is unsatisfying with no plateau in Kaplan Meier survival curves. Similar to most lymphomas, MCLs occur predominantly in the elderly with a median age at diagnosis of 65 years and is more frequent in males (ratio 3--4:1) \[[@CR10], [@CR11]\]. MCL has several features clearly differentiating it from other lymphomas. Besides its distinct morphology and immunophenotype, it has a pathognomonic chromosomal translocation, t(11;14) which causes a fusion of the cyclin D1 gene to the immunoglobulin heavy chain promoter leading to constitutive expression of cyclin D1. This is a diagnostic hallmark of the disease and of high pathobiological relevance as cyclin D1 plays a major role in cell cycle control and therefore in proliferation (see below). MCL also has a distinct clinical course and is frequently diagnosed in advanced stages. Except for a few indolent cases, MCL typically has a rapid growth requiring immediate treatment, which places MCL in clinical proximity to other aggressive lymphomas such as diffuse large B cell lymphoma (DLBCL). It also responds to similar immune-chemotherapeutic treatments (e.g., a combination of the anti-CD20 antibody rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)). Such treatment paradigms in MCL have been refined in recent years, and the clinical outcome has been significantly improved \[[@CR12]\]. In fact, younger and fit patients treated upfront with intensified protocols like R-CHOP/R-DHAP (rituximab, dexamethasone, high-dose AraC, cisplatin) followed by high-dose chemotherapy with subsequent autologous stem cell transplantation or R-Hyper-CVAD/MA (rituximab with cyclophosphamide, doxorubicin, vincristine, dexamethasone, methotrexate, AraC) have a median progression-free survival of more than 7 years \[[@CR13]--[@CR16]\]. Very recent data suggest that survival after autologous stem cell transplantation can be further improved by rituximab maintenance therapy over 3 years \[[@CR17]\]. Also, even elderly patients achieve ongoing remissions due to better tolerated R-bendamustine \[[@CR18]\]. Nevertheless, in contrast to other aggressive lymphomas, after achieving remission of the disease, MCL usually relapse within several years. In this situation, treatment options are limited. Previously, only few patients could be salvaged with very aggressive treatments including allogeneic stem cell transplantation \[[@CR19]\]. In recent years, however, several molecularly targeted therapeutic strategies have been introduced that have further improved the outcome of relapsed MCL patients not eligible for or prior to allogeneic stem cell transplantation (see below). In this regard, targeting the B cell receptor signaling pathway in MCL has been the most promising step forward, both in view of understanding the pathobiology of this disease as well as in view of advancing its treatment. These two issues will be reviewed in the following sections.

Overview on BCR development {#Sec2}
===========================

The B cell receptor consists of a membrane-bound immunoglobulin that is associated with the transmembrane proteins CD79a and CD79b \[[@CR20]\]. The latter facilitate signal transduction into the cell via phosphorylation of their cytoplasmic immunoreceptor tyrosine-based activation motifs (ITAMs) after binding of the ligand to the immunoglobulin \[[@CR20]--[@CR22]\]. The immunoglobulin itself consists of two identical light and two identical heavy chains which together form a Y-shaped molecule that harbors two identical antigen-binding sites at the N-terminal ends. Antigen binding is facilitated by three highly variable regions, called complementarity determining regions (CDRs), which are located in the variable domains of each immunoglobulin chain \[[@CR23]\]. In contrast to most other proteins, the gene sequence of the variable immunoglobulin regions is not directly encoded in the germline. Instead, the development of a functional BCR requires multiple chromosomal rearrangements and targeted induction of point mutations to generate a very specific BCR with high affinity against a foreign antigen but no reactivity against self-antigens \[[@CR3], [@CR23]\]. This process includes a random rearrangement of specific heavy chain gene segments called V(ariable)-, D(iversification), and J(oining)-gene segment as well as V- and J-gene segments of the light chain \[[@CR24]\]. The CDR3-regions of the heavy and light chains are formed independently of antigen contact by the combination of the V-(, D-) and J-gene segments in the bone marrow (reviewed in \[[@CR23]\]). After successful recombination of the gene segments on one allele, the other allele becomes silenced (allelic exclusion) to ensure that every B cell is committed to only one distinct BCR \[[@CR25], [@CR26]\].

With a recombined BCR, the naïve B cells migrate towards the secondary lymph organs where they come in contact with foreign antigens. Germinal centers (GCs) are formed in the lymph follicle, and naïve B cells are displaced from the GCs leading to the formation of an own compartment called the B cell mantle, the differentiation stage at which mantle cell lymphoma occurs. Within the GCs, the B cells actively mutate their BCR to further increase its affinity to the encountered antigen \[[@CR23], [@CR24], [@CR27]\].

The B cell receptor and its involvement in genetic alterations in mature B cell neoplasms {#Sec3}
=========================================================================================

The abovementioned process of genetic recombination is tightly controlled. Nevertheless, erroneous DNA recombination or mutations in checkpoint proteins can result in B cells with the ability to proliferate and eventually form B cell lymphomas \[[@CR4]\]. Some of these have specific chromosomal translocations bringing oncogenes under the control of the immunoglobulin (Ig) heavy chain promoter on chromosome 14q32 \[[@CR4], [@CR8]\]. In rare cases, these oncogenes juxtapose to the κ-or λ-promoter (on chromosome 2 or 22, respectively) \[[@CR4], [@CR28]\]. Since immunoglobulin promoters are highly active in B cells, the translocated oncogenes are overexpressed.

The genetic hallmark in MCL is the chromosomal translocation t(11;14)(q13;q32). This aberration leads to immunoglobulin promoter-driven constitutive expression of the cell cycle regulator Cyclin D1 (encoded by the CCND1 gene), which is usually not expressed in B cells \[[@CR29]\]. Cyclin D1 dimerizes with cyclin-dependent-kinases (CDK4/6) which, in turn, phosphorylate the retinoblastoma (Rb) tumor suppressor protein \[[@CR30]\]. Phosphorylation inactivates the Rb protein, enabling the cell to switch from the G1- to the S-phase in the cell cycle and to proliferate. Some MCL cases without the specific CCND1 translocation but similar morphological appearance have been described, as well \[[@CR31]--[@CR35]\]. However, these often carry translocations of other cyclin genes like CCND2 or CCND3 \[[@CR33]--[@CR35]\].

Of note, B cells in healthy individuals may also harbor chromosomal translocations like the ones found in B cell lymphoma \[[@CR36], [@CR37]\]. The chromosomal aberrations deemed 'specific' in the lymphoma B cells are therefore probably only an important first step in lymphoma development, and the interplay of additional mutations are required for the B cell to undergo malignant transformation \[[@CR33]\]. In line with this hypothesis, MCL shows a massive dysregulation in the RNA levels of multiple cell cycle-related and anti-apoptotic proteins \[[@CR33], [@CR38]\].

As outlined above, the major functional role of a B cell is the expression of a BCR and, upon its terminal differentiation into a plasma cell, the secretion of highly specific immunoglobulins. All B cells keep expressing their clone-specific immunoglobulin throughout the life span of the individual cell. In recent years, it became increasingly clear that the BCR retains its important role for survival and cell proliferation even after transformation of the B cells in many if not most B cell neoplasms \[[@CR4]\]. The BCR in lymphoma B cells has received tremendous interest after several studies showed an activated BCR-signaling pathway in these cells, and early clinical studies with BCR pathway inhibitors have yielded very promising results in lymphoma patients (see below). In fact, an increasing body of evidence, gained in recent years, strongly supports the theory that the BCR plays an important functional role in the pathogenesis and progression of several lymphomas. This is particularly well characterized for diffuse large B cell lymphoma (DLBCL) and for chronic lymphocytic leukemia (CLL). For example, the gene expression profiling of lymphoma cells separates DLBCL into two distinct sub-entities---one of them characterized by ongoing BCR signaling \[[@CR39]--[@CR41]\] and consequently designated as activated B cell-like (ABC-) DLBCL \[[@CR39], [@CR40], [@CR42]\]. In CLL, the role of the B cell receptor is even more pronounced. CLL cases with mutated immunoglobulins (M-CLL) have a more indolent course of their disease and a more favorable clinical outcome compared to patients with unmutated BCRs (UM-CLL) \[[@CR43]\]. Moreover, the immunoglobulin repertoire in CLL B cells is much less diverse than expected if transformation occurred randomly in a given B cell. In the latter scenario, one would expect an almost unlimited diversity of different B cell receptors in CLL with unique BCR rearrangements in all individual patients. However, this is not the case. For example, there are multiple BCR-stereotypes with the same variable heavy chain regions and identical or highly similar CDR3 regions \[[@CR44]\]. In addition, CLL can be categorized into only few classes of distinct patterns of epitope recognition \[[@CR45]\]. These studies strongly point towards shared epitopes recognized by B cell receptors of different CLL patients \[[@CR44]\]. Although not quite as striking as in CLL, studies in MCL have revealed a similar bias with stereotypes in the immunoglobulin repertoire in MCL \[[@CR46]\] as described in detail below.

Mechanisms of BCR-activation in lymphoma {#Sec4}
========================================

The BCR and BCR signaling configurations in several B cell neoplasms suggest an antigen-driven or otherwise BCR-driven selection of B cell clones during or prior to the process of transformation. Some of the distinct mechanisms of this drive might be specific for certain entities while others could be similar among various entities. In this regard, CLL is the disease investigated in most detail so far. Several distinct epitopes and/or antigens recognized by CLL BCRs have been described. Most of them are autoantigens such as the myosin heavy chain IIA, vimentin and neoantigens generated by oxidation of proteins \[[@CR45], [@CR47]--[@CR51]\]. These findings imply that most, if not all, CLL cells derive from autoreactive B cells. This might link lymphomas to systemic autoimmune disorders \[[@CR47]\]. A subset of MCL samples also showed autoantigen binding (see below).

In addition, a large proportion of CLL cells show cell-autonomous BCR signaling induced by self-recognition of the BCR \[[@CR52], [@CR53]\]. This unusual cell activation mechanism seems to be a unique feature of CLL cells and has not been described in other entities so far. Other lymphoma subtypes may use different ways of BCR signaling activation instead, such as mutated CD79 ITAMs which result in the formation of BCR clusters similar to activated BCRs and thus also maintain a chronic active BCR signaling, as described in about 20% of ABC-DLBCL \[[@CR41]\]. MCL cells, however, show no autonomous signaling and harbor no mutations in the CD79 domains \[[@CR54]\].

Follicular lymphoma cells show highly mutated immunoglobulin sequences with an acquisition of N-glycosylation sites in the antigen-binding sites \[[@CR55]--[@CR57]\]. Normally, the introduction of N-glycosylation sites is a potential mechanism for a B cell to recover from self-reactivity \[[@CR58]\] but the introduced N-glycans might also be bound by opportunistic bacteria \[[@CR59]\]. Although the MCL-derived BCRs show no enrichment of N-glycosylation sites, an infection-associated lymphoma development is a conceivable scenario in all lymphomas including MCL. Even the development of autoimmune diseases and therefore the development of autoreactive CLL cells can be linked to encountered infections \[[@CR60]--[@CR62]\].

Functional involvement of the B cell receptor in mantle cell lymphoma {#Sec5}
=====================================================================

Due to the low frequency of MCL with the resulting lack of large cohorts and patient sample repositories, the current knowledge on MCL BCRs is more limited than in CLL, follicular lymphoma (FL), or DLBCL. Thus, the antigens of MCL BCRs or the general mechanisms of their activation are very incompletely understood. Phosphoproteomic analyses revealed that the BCR signaling pathways are active in MCL cells and inhibition of key molecules of these pathways triggers apoptosis in MCL cells in vitro \[[@CR63]\]. An ongoing BCR signaling was also found in MCL samples in vivo \[[@CR64]\]. Moreover, BCR signaling inhibitors like the Bruton tyrosine kinase (BTK) inhibitor ibrutinib showed very promising efficacy in MCL patients (see below) which further suggest an important and ongoing role of the BCR in MCL \[[@CR65]\]. Recently, single cell profiling studies revealed that MCL cells showed an increased phosphorylation of multiple BCR pathway molecules, like AKT and STAT \[[@CR66], [@CR67]\]. Triggering BCR activation led to very strong BCR signaling in MCL cells, but not in CLL and healthy B cells, further highlighting the prominent role of the BCR in MCL. Of note, the phosphorylation patterns and the α-BCR-induced signaling in MCL showed a strong interpatient variability and correlate inversely with susceptibility to BTK and spleen tyrosine kinase (SYK) inhibitors in MCL \[[@CR67]\].

Despite the differences in the phosphorylation pattern, MCL and CLL patients seem to benefit more from BCR signaling inhibitors than other entities like follicular lymphoma \[[@CR65]\]. It is therefore reasonable to assume that these diseases might share more similarities, and some of the findings on the BCRs in CLL might also be observed in MCL. In line with this hypothesis, MCL BCRs show similar redundancies and stereotypies as CLL BCRs, even though in a lower proportion of cases \[[@CR46]\]. This clearly points towards an antigen-driven lymphomagenesis in both entities. However, the BCR subsets observed in MCL are different from the subsets described in CLL **(**Fig. [1](#Fig1){ref-type="fig"} **)**. In fact, only four Ig heavy chain genes (in order of their abundance: IGHV3--21, IGHV4--34, IGHV1--8, and IGHV3--23) are found in almost half of all MCL-derived BCRs \[[@CR46]\]. The isotype distribution of the light chain is biased as well, with a lambda/kappa ratio of about 2:1, representing an inversed ratio to what is found in normal B cell populations (lambda/kappa: 1:2) \[[@CR68]--[@CR70]\]. As a result of the specific expansion of a single cell clone expressing only one distinct BCR, it is also possible to determine the light chain corresponding to the identified heavy chain of the lymphoma-derived immunoglobulin in tissue samples. Although only a few studies focused on MCL light chains, the analysis of heavy and light chain pairings revealed a possible MCL subtype which is characterized by the distinct expression of the IGHV3--21 gene together with the IGLV3--19-gene \[[@CR71]\]. MCL patients of this subtype seem to have a slightly better prognosis than patients with different MCL-derived BCRs \[[@CR71]\]. The reason for this difference remains unknown so far but, once more, shows the heterogeneity of this disease.Fig. 1IGHV-gene distribution of MCL-, CLL- and naïve B cell-derived antigen receptors. Studies of the MCL BCRs revealed a biased immunoglobulin repertoire. The differences in the amount of the most abundant IGHV-genes in comparison to CLL and naïve B cells are highlighted with lines between the bars. Data are based on refs \[[@CR41], [@CR42], [@CR111]\]

Compared to other B cell lymphomas, the mutational load of MCL-derived immunoglobulins is low. Several studies showed that only a subset of 20--29% of MCL harbor immunoglobulins with more than 2% deviation from the germline sequence \[[@CR46], [@CR72]--[@CR74]\]. In CLL, this 2% cutoff was often used to distinguish between mutated and unmutated CLL, with marked prognostic implications (see above) \[[@CR43], [@CR75]\]. In MCL, however, the usefulness of this cutoff remains questionable and does not seem to be applicable. Hadzidimitriou and colleagues proposed a more detailed differentiation. They showed that 29.5% of all MCL-derived Ig heavy chains are completely unmutated (which has not been described to this extent in any other lymphoma) and only 13.8% showed more than 3% deviation from the germline sequence \[[@CR46], [@CR76]\]. The difference in the mutational load of the BCR has led to the assumption that MCL develops from two different pathways. The classical MCL derives from SOX11-positive cells with unmutated or minimally mutated IGHVs and shows a more aggressive behavior. The leukemic non-nodal MCL, on the other hand, develops from IGHV-mutated SOX-negative B cells and usually has a more indolent course \[[@CR7], [@CR38]\].

There is little knowledge on potential ongoing changes in the BCR once MCL has developed into a clinically detectable disease. Towards this end, we recently analyzed the MCL-derived immunoglobulin repertoire of two sequential biopsies of the same patient by next-generation sequencing (unpublished data). We saw virtually no ongoing mutations in the analyzed MCL-derived Ig sequences over a 4-year period, which is in great contrast to observations made in follicular lymphoma with an ongoing mutation pattern of the FL-derived immunoglobulins over time \[[@CR77]\]. However, the molecular pathogenesis of FL and MCL differs profoundly and FL-derived immunoglobulin rearrangements always have a very high mutational load. Although our observation was made only in a single patient, it might indicate that even minor mutations in the MCL-BCR could diminish the B cells' ability to proliferate and might therefore be negatively selected. Nevertheless, further analysis of a missing or ongoing mutation of MCL immunoglobulins, and lymphoma immunoglobulins in general, is needed to foster our understanding of immunoglobulin stability in these diseases. High-throughput methods like next-generation sequencing will help in the analysis of the changes which occur in the different B cell lymphomas entities over time.

Unmutated (UM) immunoglobulins are often regarded as polyreactive, and it was shown that UM-CLL-derived immunoglobulins bind to autoantigens presented by HEp-2 cells \[[@CR48]\]. A similar study with MCL-derived immunoglobulins demonstrated that about one third of all MCL-derived immunoglobulins bind HEp-2 antigens \[[@CR49]\], an observation which is confirmed by our group (unpublished data). However, this amount of autoreactive immunoglobulins in MCL is lower than the observed amount in M-CLL (approximately 56.7%) and much lower compared to UM-CLL cells which expressed autoreactive BCRs in 89.6% of all cases \[[@CR48]\]. In fact, the observed HEp-2 reactivity of MCL-derived immunoglobulins is comparable to the HEp-2 reactivity of immature B cells (approximately 40%) and is therefore slightly higher than the rate in naïve B cells (approximately 20%) \[[@CR78]\]. Nevertheless, we think that these results should be interpreted with caution as they do not necessarily prove the complete absence of autoreactive B cells in two thirds of all MCL patients. Alternatively, MCL BCRs may have a very low affinity, which would result in false-negative experiments, or may bind to autoantigens not expressed in HEp-2 cells. In light of a study which observed varying activity of the activation-induced cytidine deaminase (AID), it seems that the tumor microenvironment plays a crucial role in MCL development which is not sufficiently represented by a single cell line like HEp-2 cells \[[@CR30], [@CR79]\]. The influence of the microenvironment during lymphoma development is further highlighted in a study showing a biased usage of the IGHV1--8 gene in splenic MCL cases compared to nodal and extranodal cases \[[@CR80]\]. The observed bias in the immunorepertoire might represent a distinct immunopathogenic and antigen selection process in splenic MCLs.

Superantigenic B cell receptor interaction as a potential pathogenic factor in mantle cell lymphoma {#Sec6}
===================================================================================================

As an alternative to classical antigens which are bound by the antigen-binding site of the BCR, recent research proposed an involvement of superantigens in MCL development \[[@CR76]\]. Superantigens were first described for T cell receptors and represent proteins which bind to the framework regions (FR) of TCRs and BCRs, instead of being bound by the complementarity determining regions (CDRs) \[[@CR81], [@CR82]\]. Since the FRs are necessary for the structural integrity of the immunoglobulins, they are far less variable than CDRs. As a result, superantigens can stimulate multiple T or B cells harboring similar variable domains but not necessarily recognize the same epitope or even antigen. Over the years, several superantigens were identified that bind to different amino acid motifs in the variable domains of BCRs (reviewed in \[[@CR82]\]). One of the best-characterized immunoglobulin-binding superantigens is the *Staphylococcus aureus* protein A (SpA) \[[@CR83], [@CR84]\]. *Staphylococcus aureus* is a common pathogen. Up to 50%, the healthy population is temporarily and about 20% are persistently colonized with this bacterium \[[@CR85], [@CR86]\]. Protein A is a well-known protein in molecular biology research labs due to its strong affinity to the constant domain of IgGs and thus its usefulness during the purification of antibodies. Like most superantigens, SpA is probably expressed by *S. aureus* to evade the host immune defense by binding the antibodies at the 'wrong site' and therefore thwart the effector function of the immunoglobulin. However, in addition to the well-known ability of SpA to bind the Fc-part of the antibody, it can bind a clearly defined motif in the FR of immunoglobulins (Fig. [2](#Fig2){ref-type="fig"}). This binding motif consists of 13 amino acids at specific positions in the variable immunoglobulin domain (represented as spheres in Fig. [2](#Fig2){ref-type="fig"}), which is present in nearly all immunoglobulins with the IGHV3-family \[[@CR83]\]. SpA binding can crosslink the membrane-bound BCRs without occupying their specific antigen-binding site which can be seen in Fig. [2](#Fig2){ref-type="fig"}. Earlier studies have shown that stimulation of human blood cells with SpA in vitro leads to a biased immunoglobulin repertoire and induces selective proliferation of IGHV3-expressing B cells \[[@CR87]\]. Importantly, the IGHV3-gene family is the most abundant IGHV-family and about half of all MCL- and CLL-cells express an IGHV3-gene. Nearly every MCL-BCR expressing an IGHV3 immunoglobulin also presents the SpA motif, and it was shown that these BCRs can be activated by SpA \[[@CR76]\]. In healthy and matured B cells, the SpA motif is often mutated and the BCR cannot be activated by SpA anymore. Given the low mutational load and the biased usage of certain immunoglobulin genes like the IGHV3--21-gene in MCL, it seems to be a reasonable assumption that superantigens in general and SpA in particular might play an important role in the development and/or progression of MCL. Moreover, the intact SpA binding motif is also present in other entities like Burkitt lymphoma and CLL, raising the question whether different lymphoma entities might be caused by such triggers as well \[[@CR88], [@CR89]\]. Although merely hypothetical at this point, a superantigenic activation of a very large amount of early B cells appears to be a plausible first step in the development of lymphomas in general.Fig. 2Cartoon representation of an IGHV3-Fab domain with the Domain D of *Staphylococcus aureus* protein A (SpA)**.** Schematic depiction of the BCR on a B cell (left) and the crystallographic structure of its human Fab fragment in association with SpA (in the circle). The heavy chain is shown in blue, the light chain is shown in red and the antigen-binding site with all CDRs is highlighted in purple. In addition, the amino acids which are necessary for the interaction of SpA (orange) with the Fab are depicted by spheres. Note that all but one amino acid are located in the framework region of the Fab. Neither the light chain nor the antigen-binding site contributes to SpA binding. Image adapted from the crystallographic structure published previously \[[@CR78]\]. PDB: 1DEE

On the other hand*,* in vivo experiments showed a strong decrease of B cells expressing the IGHV3-gene after SpA exposition which is probably a result of the increased B cell proliferation and the concomitant overconsumption of cytokines and the lack of secondary signals \[[@CR90]\]. However, early lymphoma B cells might overcome this lack of signals as a result of previous mutations, and since whole B cell subpopulations are activated and proliferated, certain already mutated B cells might escape apoptosis and eventually transform into neoplasia. Although highly speculative at this point, the outlined superantigen-dependent lymphoma development could be an additional path in lymphomagenesis, besides the ones described above such as the cell-autonomous signaling in CLL and the---also infection-associated---development of FL via bacterial lectins. Multiple further superantigens are known that are able to bind to immunoglobulins from MCL, CLL, and Burkitt lymphoma \[[@CR46], [@CR88], [@CR89]\]. These include the carbohydrate I/i (binding to IGHV4--34) and the *Peptostreptococcus magnus* protein L (binding to κ-light chains) \[[@CR91], [@CR92]\].

Despite these advances in understanding, more research is necessary to evaluate if an ongoing infection promotes or is needed for lymphoma progression, if the eradication of the infection may improve clinical outcome, or if a single superantigenic trigger might be sufficient for lymphoma development followed by other B cell activation mechanisms promoting lymphoma progression.

Targeting the BCR signaling cascade in MCL {#Sec7}
==========================================

The introduction of the anti-CD20 antibody rituximab almost two decades ago has tremendously altered the treatment paradigms of mature B cell lymphoma \[[@CR93], [@CR94]\]. This has remained the biggest advancement in lymphoma therapy in a very long time, making it part of the standard treatment in all CD20-positive lymphomas (i.e., the majority of lymphomas). Although rituximab is also effective in MCL and enhances its sensitivity towards chemotherapy \[[@CR95]\], MCL continues to have a prognosis considerably worse than most other lymphomas. And this is despite recent advances in upfront treatment (see above) and inclusion of treatment algorithms such as high-dose chemotherapy and stem cell transplantation into first line therapy settings that are used only in the relapsed or refractory situation in other lymphoma entities. Except for the few indolent forms of MCL, the majority of patients relapse within years after initial treatment and treatment options have been limited in this situation. The recognition of the role of the BCR in the pathobiology of several lymphoma entities has also prompted the development of a class of novel drugs with profound activity in these diseases. In consequence, inhibition of the BCR downstream signaling cascade has evolved as a promising new treatment option (reviewed in \[[@CR65]\]), but not for all lymphomas alike. Most data exist on ibrutinib which inhibits Bruton tyrosine kinase (see below). The observed activity in clinical trials on various lymphoma entities ranges from efficacy in almost all patients such as in CLL \[[@CR96]\] to hardly any significant activity as a monotherapy in GCB (germinal center B cell like) subtypes of DLBCL \[[@CR97]\]. In view of the fact that most MCL cells appear to depend on BCR signaling, it has been pertinent to test BCR signaling inhibition in this entity. In fact, it has turned out that this approach is a major step forward in the treatment of relapsed and refractory patients and in the future maybe as part of the first line treatment in MCL (see below).

There are several key molecules involved in BCR signaling (Fig. [3](#Fig3){ref-type="fig"}). After BCR crosslinking and subsequent phosphorylation of the CD79 ITAMs, the spleen tyrosine kinase (SYK) is recruited to the ITAMs. Thus, this first step in the BCR signaling cascade is the first potential drug target to block B cell proliferation \[[@CR98]\]. Interestingly, SYK is overexpressed in many clinical cases of MCL and in several MCL cell line models and SYK inhibition leads to apoptosis induction in vitro, which is particularly strong in cells with high SYK expression \[[@CR63], [@CR99]\]. However, in an early phase clinical study, SYK-inhibition did not yield the expected efficacy and resulted in only limited objective response rates (ORR), especially compared to other BCR-inhibitors in CLL patients \[[@CR100]\].Fig. 3Direct and indirect targeting of the B cell receptor signaling pathway. Direct inhibition of BCR signaling is highlighted in red, potential additional and/or synergistic inhibition strategies with available drugs or drugs in advanced clinical development are shown in blue. Only one example per class of inhibitors is shown

Another key element in the BCR-signaling cascade is BTK. This kinase directly affects B cell differentiation and proliferation and thus is a valuable target for inhibition \[[@CR101]\]. In addition, BTK is overexpressed in MCL and CLL cells \[[@CR102], [@CR103]\]. Ibrutinib is a highly selective BTK inhibitor. It binds covalently to Cys-481 of BTK, leading to an irreversible inhibition of its kinase activity \[[@CR104]\]. Several clinical trials showed very promising response rates of ibrutinib in patients with MCL and CLL \[[@CR105]--[@CR107]\], making these two entities paradigmatic for clinical benefits of BCR signaling inhibition. In a pivotal phase II trial, the BTK inhibitor achieved a response rate of 68% (CR 21%) in heavily pretreated MCL patients \[[@CR105]\]. Also ibrutinib has been shown to be superior to a previously established MCL salvage treatment, with the mTOR inhibitor temsirolimus. In this trial, it achieved considerably better response rates (72 vs. 40%) and median progression-free survival was markedly improved (14.6 vs 6.2 months) \[[@CR108]\]. Consequently, BCR-targeted therapeutic concepts have been adapted as one of the standard regimens in relapsed MCL \[[@CR12]\]. Nevertheless, approximately one third of the MCL patients did not respond to ibrutinib treatment. Also, multiple MCL cell lines are intrinsically resistant against this drug in vitro and early progressions under ibrutinib monotherapy with a very aggressive course in the clinical setting have been observed \[[@CR30], [@CR109], [@CR110]\]. This resistance might be related to the strong interpatient molecular variability of the BCR activation pattern in MCL characterized previously \[[@CR67]\]. Some MCL cells may activate the NF-κB-pathway through the BCR-independent NIK kinase pathway, which in turn might be an additional treatment target \[[@CR109]\]. Nevertheless, ibrutinib has been approved as a treatment option after failure of previous therapy in MCL and is currently probably the most widely applied targeted treatment strategy in this setting. Ongoing clinical trials such as the TRIANGLE trial (ClinicalTrials.gov; NCT02858258) also evaluate BTK inhibition as part of the intensive multimodal front line therapy in MCL, and in view of the novel understanding of MCL pathobiology, we believe it to be very likely that the results of such trials will be positive.

Also, since nearly every downstream signaling molecule in the BCR pathway could be the 'Achilles heel' of the lymphoma, further targets are being evaluated in preclinical and clinical studies. For instance, inhibitors of PI3K, PKC and AKT are currently under development and tested for their effectiveness \[[@CR101], [@CR111]--[@CR113]\]. In vitro results suggest a significant synergy of combined approaches targeting the BCR pathway.

Conclusions {#Sec8}
===========

In the past 20 years, our knowledge about the molecular similarities and differences of the lymphoma entities has greatly increased. As outlined above, this has led to the development of novel treatment options and an improved survival of lymphoma patients. Nevertheless, not all patients seem to benefit from these new agents and the potential to predict outcome after certain treatments is limited. Although established prognostic clinical scores like the Mantle Cell Lymphoma International Prognostic Index \[[@CR114], [@CR115]\] or certain molecular features help to guide intensity of front line treatment, there continues to be a need for more personalized therapy of lymphoma in MCL. More research is required to identify the various causes of resistance to the various treatments like ibrutinib in MCL. Besides the urgent need for new predictive biomarkers, it is important to further deepen our understanding of how the different lymphomas develop in the first place. The analysis of the BCR repertoire in mature B cell neoplasms points towards an antigen involvement in the genesis of several lymphomas which might even reveal the opportunity to prevent the actual tumor development. However, despite recent advances such as the discovery of superantigens activating MCL BCRs, there is still too little knowledge about potential BCR-interacting antigens in MCL cells not harboring superantigen-binding sites. While a few MCL BCRs might bind to autoantigens similar to binding patterns described in CLL, the activation mechanisms of other MCL BCRs remains elusive. In principle, there appear to be four potential ways of triggering an activated B cell receptor in the pathogenetic course towards mantle cell lymphoma development: (i) "classical antigenic drive" by antigen binding to the CDRs of the BCR, (ii) antigen-independent autologous signaling of the BCR, e.g., by aberrations within CD79, (iii) superantigen-triggered BCR activation, or (iv) a combination of (i) and (iii) with superantigens facilitating BCR activation by low level (may be due to low affinity) antigen binding or CD79 aberrations (Fig. [4](#Fig4){ref-type="fig"}). Future studies have to clarify at which time point in lymphomagenesis the antigenic stimulus takes place and whether it might be compensated by other low affinity interactions during later stages of lymphoma development. Answering these questions will further improve the perspective towards the cure of an increasing percentage of MCL patients in the near future.Fig. 4Four potential ways of B cell receptor activation in the pathogenesis of mantle cell lymphoma. a Antigen binding to the CDR3 of the BCR. b Antigen-independent autologous signaling of the BCR. c Superantigen-triggered BCR activation. d Superantigens facilitating BCR activation by classical may be low affinity antigen binding or CD79 aberrations
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:   Objective response rate

PI3K

:   Phosphoinositol kinase

PKC

:   Protein kinase C

Rb

:   Retinoblastoma

R-CHOP

:   Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone

R-DHAP

:   Rituximab, dexamethasone, high-dose AraC, cisplatin

R-Hyper-CVAD/MA

:   Rituximab with cyclophosphamide, doxorubicine, vincristine, dexamethasone, methotrexate, AraC

SpA

:   *Staphylococcus aureus* protein A

SYK

:   Spleen tyrosine kinase

TCR

:   T cell receptor

UM-CLL

:   Chronic lymphocytic leukemia with unmutated immunoglobulins
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